nach oben

Erschienen in:

07.05.2018 | Research Article

The Utility of [¹⁸F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography

verfasst von: Corinne Beinat, Tom Haywood, Yun-Sheng Chen, Chirag B. Patel, Israt S. Alam, Surya Murty, Sanjiv Sam Gambhir

Erschienen in: Molecular Imaging and Biology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is a strong, unmet need for superior positron emission tomography (PET) imaging agents that are able to measure biochemical processes specific to prostate cancer. Pyruvate kinase M2 (PKM2) catalyzes the concluding step in glycolysis and is a key regulator of tumor growth and metabolism. Elevation of PKM2 expression was detected in Gleason 8–10 tumors compared to Gleason 6–7 carcinomas, indicating that PKM2 may potentially be a marker of aggressive prostate cancer. We have recently reported the development of a PKM2-specific radiopharmaceutical [¹⁸F]DASA-23 and herein describe its evaluation in cell culture and preclinical models of prostate cancer.

Procedure

The cellular uptake of [¹⁸F]DASA-23 was evaluated in a panel of prostate cancer cell lines and compared to that of [¹⁸F]FDG. The specificity of [¹⁸F]DASA-23 to measure PKM2 levels in cell culture was additionally confirmed through the use of PKM2-specific siRNA. PET imaging studies were then completed utilizing subcutaneous prostate cancer xenografts using either PC3 or DU145 cells in mice.

Results

[¹⁸F]DASA-23 uptake values over 60-min incubation period in PC3, LnCAP, and DU145 respectively were 23.4 ± 4.5, 18.0 ± 2.1, and 53.1 ± 4.6 % tracer/mg protein. Transient reduction in PKM2 protein expression with siRNA resulted in a 50.1 % reduction in radiotracer uptake in DU145 cells. Small animal PET imaging revealed 0.86 ± 0.13 and 1.6 ± 0.2 % ID/g at 30 min post injection of radioactivity in DU145 and PC3 subcutaneous tumor bearing mice respectively.

Conclusion

Herein, we evaluated a F-18-labeled PKM2-specific radiotracer, [¹⁸F]DASA-23, for the molecular imaging of prostate cancer with PET. [¹⁸F]DASA-23 revealed rapid and extensive uptake levels in cellular uptake studies of prostate cancer cells; however, there was only modest tumor uptake when evaluated in mouse subcutaneous tumor models.

Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785–2808CrossRef

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef

Brawley OW (2012) Prostate cancer epidemiology in the United States. World J Urol 30:195–200CrossRef

Kavanagh JP (1994) Isocitric and citric acid in human prostatic and seminal fluid: implications for prostatic metabolism and secretion. Prostate 24:139–142CrossRef

Medrano A, Fernandez-Novell JM, Ramio L et al (2006) Utilization of citrate and lactate through a lactate dehydrogenase and ATP-regulated pathway in boar spermatozoa. Mol Reprod Dev 73:369–378CrossRef

Mycielska ME, Patel A, Rizaner N, Mazurek MP, Keun H, Patel A, Ganapathy V, Djamgoz MBA (2009) Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer. BioEssays 31:10–20CrossRef

Wong N, Yan J, Ojo D, de Melo J, Cutz JC, Tang D (2014) Changes in PKM2 associate with prostate cancer progression. Cancer Investig 32:330–338CrossRef

Jadvar H (2013) Molecular imaging of prostate cancer with PET. J Nucl Med 54:1685–1688CrossRef

Jadvar H (2009) FDG PET in prostate Cancer. PET Clinics 4:155–161CrossRef

10.

Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS (2005) Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 4:91–97CrossRef

11.

Liu IJ, Zafar MB, Lai Y-H, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57:108–111CrossRef

12.

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362PubMed

13.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMed

14.

Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552–558CrossRef

15.

Iagaru A (2017) Will GRPR compete with PSMA as a target in prostate cancer? J Nucl Med 58:1883–1884CrossRef

16.

Iagaru A, Minamimoto R, Loening A et al (2016) Biochemically recurrent prostate cancer: ⁶⁸Ga-RM2 (formerly known as ⁶⁸Ga-Bombesin or BAY86-7548) PET/MRI is superior to conventional imaging. J Nucl Med 57:466CrossRef

17.

Nagasaki S, Nakamura Y, Maekawa T et al (2012) Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor betacx in human prostate carcinoma. Neoplasma 59:224–232CrossRef

18.

Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Müntener M, Kristiansen G (2012) Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate 72:318–325CrossRef

19.

Wong N, De Melo J, Tang D (2013) PKM2, a central point of regulation in Cancer metabolism. Int J Cell Biol 2013:242513CrossRef

20.

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230–233CrossRef

21.

Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G (1994) L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 424:177–185CrossRef

22.

Bluemlein K, Grüning N-M, Feichtinger RG, Lehrach H, Kofler B, Ralser M (2011) No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2:393–400CrossRef

23.

Beinat C, Alam IS, James ML, Srinivasan A, Gambhir SS (2017) Development of [¹⁸F]DASA-23 for imaging tumor glycolysis through noninvasive measurement of pyruvate kinase M2. Mol Imaging Biol 19:665–672CrossRef

24.

Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R (2002) Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 41:425–429CrossRef

25.

Sonni I, Baratto L, Iagaru A (2017) Imaging of prostate cancer using Gallium-68 labeled Bombesin. PET Clinics 12:159–171CrossRef

26.

Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, van Velthoven R, Flamen P (2016) Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 43:195–196CrossRef

27.

Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E (2016) Follicular thyroid adenoma showing avid uptake on ⁶⁸Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 41:331–332CrossRef

28.

Kobe C, Maintz D, Fischer T, Drzezga A, Chang DH (2015) Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med 40:897–898CrossRef

29.

Rischpler C, Maurer T, Schwaiger M, Eiber M (2016) Intense PSMA-expression using ⁶⁸Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging 43:193–194CrossRef

30.

Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM, Behrendt FF (2015) [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 42:210–214CrossRef

31.

Roivainen A, Kähkönen E, Luoto P et al (2013) Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation Dosimetry of 68Ga Bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med 54:867–872CrossRef

32.

Stephens A, Loidl WC, Beheshti M, Jambor I, Kemppainen J, Bostrom P, Kahkonen E, Berndt M, Mueller A, Minn H, Langsteger W (2016) Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy. J Clin Oncol 34:80CrossRef

33.

Chlenski A, K-i N, Ketels KV et al (2001) Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47:66–75CrossRef

34.

Andersen KF, Divilov V, Sevak K, Koziorowski J, Lewis JS, Pillarsetty NVK (2014) Influence of free fatty acids on glucose uptake in prostate cancer cells. Nucl Med Biol 41:254–258CrossRef

35.

Witney TH, James ML, Shen B, Chang E, Pohling C, Arksey N, Hoehne A, Shuhendler A, Park JH, Bodapati D, Weber J, Gowrishankar G, Rao J, Chin FT, Gambhir SS (2015) PET imaging of tumor glycolysis downstream of hexokinase through noninvasive measurement of pyruvate kinase M2. Sci Transl Med 7(310):310ra169CrossRef

Titel: The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography
verfasst von: Corinne Beinat
Tom Haywood
Yun-Sheng Chen
Chirag B. Patel
Israt S. Alam
Surya Murty
Sanjiv Sam Gambhir
Publikationsdatum: 07.05.2018
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 6/2018
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-1194-y

Optimization of a Labeling and Kit Preparation Method for Ga-68 Labeled DOTATATE, Using Cation Exchange Resin Purified Ga-68 Eluates Obtained from a Tin Dioxide 68Ge/68Ga Generator

Research Article

Performance Evaluation of a Dedicated Preclinical PET/CT System for the Assessment of Mineralization Process in a Mouse Model of Atherosclerosis

Research Article

Metabolic and Molecular Imaging with Hyperpolarised Tracers

Review Article

Mass Spectrometry Imaging and Integration with Other Imaging Modalities for Greater Molecular Understanding of Biological Tissues

Open Access
Review Article

In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer

Open Access
Research Article

Tri-modal In vivo Imaging of Pancreatic Islets Transplanted Subcutaneously in Mice

Research Article

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

12.01.2025
Computertomografie
Nachrichten

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

09.01.2025
Mammografie
Nachrichten

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Utility of [¹⁸F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography